Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion.The two companies will start with four development programs that use different ways to potentially treat obesity,

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop multiple oral small molecule therapies for key GPCR targets,

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.